KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Esperion Therapeutics (ESPR) Interest Expenses (2019 - 2025)

Esperion Therapeutics' Interest Expenses history spans 7 years, with the latest figure at $22.6 million for Q4 2025.

  • For Q4 2025, Interest Expenses fell 8.2% year-over-year to $22.6 million; the TTM value through Dec 2025 reached $84.6 million, up 25.37%, while the annual FY2025 figure was $84.6 million, 42.79% up from the prior year.
  • Interest Expenses reached $22.6 million in Q4 2025 per ESPR's latest filing, up from $22.1 million in the prior quarter.
  • In the past five years, Interest Expenses ranged from a high of $24.7 million in Q4 2024 to a low of $8.1 million in Q1 2021.
  • Average Interest Expenses over 5 years is $15.7 million, with a median of $14.4 million recorded in 2022.
  • Peak YoY movement for Interest Expenses: skyrocketed 177.07% in 2021, then decreased 8.2% in 2025.
  • A 5-year view of Interest Expenses shows it stood at $13.4 million in 2021, then grew by 6.69% to $14.3 million in 2022, then grew by 5.08% to $15.1 million in 2023, then skyrocketed by 63.76% to $24.7 million in 2024, then decreased by 8.2% to $22.6 million in 2025.
  • Per Business Quant, the three most recent readings for ESPR's Interest Expenses are $22.6 million (Q4 2025), $22.1 million (Q3 2025), and $20.5 million (Q2 2025).